Wo, Jennifer Y.; Clark, Jeffrey W.; Eyler, Christine E.; Mino-Kenudson, Mari; Klempner, Samuel J.; Allen, Jill N.; Keane, Florence K.; Parikh, Aparna R.; Roeland, Eric; Drapek, Lorraine C.; Ryan, David P.; Corcoran, Ryan B.; Van Seventer, Emily; Fetter, Isobel J.; Shahzade, Heather A.; Khandekar, Melin J.; Lanuti, Michael; Morse, Christopher R.; Heist, Rebecca S.; Ulysse, Christine A.; Christopher, Benjamin; Baglini, Christian; Yeap, Beow Y.; Mullen, John T.; Hong, Theodore S. published the artcile< Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas>, Computed Properties of 1492-18-8, the main research area is FOLFIRINOX chemoradition gastroesophageal adenocarcinomas.
We performed a NCI-sponsored, prospective study of neoadjuvant FOLFIRINOX followed by chemoradiation with carboplatin/paclitaxel followed by surgery in patients with locally advanced gastric or gastroesophageal cancer. Patients and Methods: The primary objective was to determine completion rate of neoadjuvant FOLFIRINOX x 8 followed by chemoradiation. Secondary endpoints were toxicity and pathol. complete response (pCR) rate. Exploratory anal. was performed of circulating tumor DNA (ctDNA) to treatment response. From Oct. 2017 to June 2018, 25 patients were enrolled. All patients started FOLFIRINOX, 92% completed all eight planned cycles, and 88% completed chemoradiation. Twenty (80%) patients underwent surgical resection, and 7 had a pCR (35% in resected cohort, 28% intention to treat). Tumor-specific mutations were identified in 21 (84%) patients, of whom 4 and 17 patients had undetectable and detectable ctDNA at baseline, resp. Presence of detectable post-chemoradiation ctDNA (P = 0.004) and/or postoperative ctDNA (P = 0.045) were associated with disease recurrence. Here we show neoadjuvant FOLFIRINOX followed by chemoradiation for locally advanced gastroesophageal cancer is feasible and yields a high rate of pCR. ctDNA appears to be a promising predictor of postoperative recurrence.
Clinical Cancer Research published new progress about Animal gene Role: BSU (Biological Study, Unclassified), PRP (Properties), BIOL (Biological Study) (AKTl1). 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Computed Properties of 1492-18-8.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts